Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Existing investors including Foxconn, SK Telecom and iA Financial could buy up to $80m of shares in the medical imaging system developer's initial public offering.

UCSF spinout Mission Bio has pushed its overall funding to more than $120m following a series C round led by Novo Growth.

Agilent Ventures has taken part in a Novo Growth-led round that brought the precision medicine technology developer's overall funding to more than $120m.

Amid the covid-19 pandemic, interest in life sciences is now perhaps at its highest. This is true in corporate venture capital and three of the multimillion-dollar stories we reported in mid-August corroborate this.

Kunlun Tech returned to reinvest in a $21.6m round for the cardiovascular imaging system provider, which is also working on a device for coronavirus diagnosis.

Boehringer Ingelheim Venture Fund led an $11.2m series A round for Bodyport, developer of a cardiovascular disease detection system.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.